Centaurus Financial Inc. Sells 330 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Centaurus Financial Inc. cut its holdings in West Pharmaceutical Services, Inc. (NYSE:WST) by 52.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 295 shares of the medical instruments supplier’s stock after selling 330 shares during the period. Centaurus Financial Inc.’s holdings in West Pharmaceutical Services were worth $104,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of WST. Quarry LP boosted its holdings in West Pharmaceutical Services by 155.3% in the 4th quarter. Quarry LP now owns 97 shares of the medical instruments supplier’s stock worth $34,000 after buying an additional 59 shares during the period. Planned Solutions Inc. bought a new position in West Pharmaceutical Services in the 4th quarter worth approximately $39,000. Addison Advisors LLC boosted its holdings in West Pharmaceutical Services by 28.9% in the 4th quarter. Addison Advisors LLC now owns 183 shares of the medical instruments supplier’s stock worth $64,000 after buying an additional 41 shares during the period. Livforsakringsbolaget Skandia Omsesidigt boosted its holdings in West Pharmaceutical Services by 90.0% in the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 190 shares of the medical instruments supplier’s stock worth $67,000 after buying an additional 90 shares during the period. Finally, Lindbrook Capital LLC boosted its holdings in West Pharmaceutical Services by 46.0% in the 4th quarter. Lindbrook Capital LLC now owns 235 shares of the medical instruments supplier’s stock worth $83,000 after buying an additional 74 shares during the period. 93.90% of the stock is owned by institutional investors.

West Pharmaceutical Services Stock Down 4.2 %

Shares of NYSE:WST opened at $322.07 on Thursday. The firm has a fifty day moving average price of $349.89 and a two-hundred day moving average price of $361.38. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.61 and a quick ratio of 1.95. West Pharmaceutical Services, Inc. has a one year low of $310.00 and a one year high of $415.73. The company has a market cap of $23.46 billion, a price-to-earnings ratio of 42.49, a PEG ratio of 5.93 and a beta of 1.01.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, April 25th. The medical instruments supplier reported $1.56 EPS for the quarter, beating the consensus estimate of $1.29 by $0.27. West Pharmaceutical Services had a net margin of 19.42% and a return on equity of 20.57%. The firm had revenue of $695.40 million during the quarter, compared to the consensus estimate of $670.62 million. During the same period last year, the firm earned $1.98 EPS. The business’s quarterly revenue was down 3.0% compared to the same quarter last year. Analysts anticipate that West Pharmaceutical Services, Inc. will post 7.76 EPS for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, August 7th. Shareholders of record on Wednesday, July 31st will be issued a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.25%. The ex-dividend date is Wednesday, July 31st. West Pharmaceutical Services’s payout ratio is 10.55%.

Insider Buying and Selling at West Pharmaceutical Services

In other West Pharmaceutical Services news, CEO Eric Mark Green sold 66,000 shares of the firm’s stock in a transaction on Tuesday, May 7th. The shares were sold at an average price of $366.65, for a total value of $24,198,900.00. Following the completion of the transaction, the chief executive officer now directly owns 152,908 shares of the company’s stock, valued at approximately $56,063,718.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, CEO Eric Mark Green sold 66,000 shares of the firm’s stock in a transaction on Tuesday, May 7th. The shares were sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the sale, the chief executive officer now owns 152,908 shares in the company, valued at approximately $56,063,718.20. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Silji Abraham sold 1,800 shares of the firm’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $330.78, for a total transaction of $595,404.00. Following the sale, the senior vice president now owns 2,860 shares in the company, valued at approximately $946,030.80. The disclosure for this sale can be found here. Insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.